kabutan

Meiji Holdings Co., Ltd.(2269) Summary

2269
TSE Prime
Meiji Holdings Co., Ltd.
3,931
JPY
+34
(+0.87%)
Mar 13, 3:30 pm JST
24.66
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
3,930
Mar 13, 5:29 pm JST
Summary Chart Historical News Financial Result
PER
19.7
PBR
1.40
Yield
2.67%
Margin Trading Ratio
5.26
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
3,900 JPY 24.49 USD
Previous Close Mar 12
3,897 JPY 24.51 USD
High Mar 13, 10:07 am
3,981 JPY 25.03 USD
Low Mar 13, 9:00 am
3,891 JPY 24.43 USD
Volume
1,780,400
Trading Value
7.00B JPY 0.04B USD
VWAP
3933.89 JPY 24.68 USD
Minimum Trading Value
393,100 JPY 2,466 USD
Market Cap
1.11T JPY 6.98B USD
Number of Trades
3,841
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
2,766
1-Year High May 9, 2025
11,842
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 123,300 233,800 1.90
Feb 27, 2026 109,500 263,200 2.40
Feb 20, 2026 81,500 237,400 2.91
Feb 13, 2026 77,600 249,100 3.21
Feb 6, 2026 74,700 244,300 3.27
Company Profile
Meiji Holdings Co., Ltd. was formed through the integration of Meiji Seika and Meiji Dairies. It is the largest company in the confectionery and dairy industries. The company's pharmaceutical business is experiencing rapid growth, and it is expanding globally.
Sector
Foods
Meiji Holdings Co., Ltd. operates in two business segments: Food and Pharmaceuticals. In the Food segment, the company handles a wide range of products including dairy products, confectioneries, nutritional foods, and animal feed, conducting business through numerous subsidiaries and affiliated companies both domestically and internationally. The Pharmaceutical segment focuses primarily on prescription drugs and veterinary medicines, manufacturing and selling these products through domestic and overseas subsidiaries. As a pure holding company, Meiji Holdings is responsible for formulating group-wide strategies and managing operations. Meiji Co., Ltd. is positioned as the core company in the food business, while Meiji Seika Pharma Co., Ltd. and KM Biologics Co., Ltd. are the core companies in the pharmaceutical business. The company is also focusing on global expansion, with numerous overseas subsidiaries, particularly in Asia.